RAS structure is central to its function. We study the structure and function of disease-associated RAS mutants and multimeric RAS complexes.
The founding project for the Westover lab was to develop KRAS G12C inhibitors. KRAS G12C drugs are now FDA approved. We are working to discover more.
Targeted kinase inhibitors have altered the natural history of certain lethal cancers and are useful research tools. We are working to discover more.
Drug resistance occurs commonly in response to targeted therapies. We study resistance to develop therapeutic strategies and to learn about biology.